Your browser doesn't support javascript.
loading
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
Newell, Felicity; Pires da Silva, Ines; Johansson, Peter A; Menzies, Alexander M; Wilmott, James S; Addala, Venkateswar; Carlino, Matteo S; Rizos, Helen; Nones, Katia; Edwards, Jarem J; Lakis, Vanessa; Kazakoff, Stephen H; Mukhopadhyay, Pamela; Ferguson, Peter M; Leonard, Conrad; Koufariotis, Lambros T; Wood, Scott; Blank, Christian U; Thompson, John F; Spillane, Andrew J; Saw, Robyn P M; Shannon, Kerwin F; Pearson, John V; Mann, Graham J; Hayward, Nicholas K; Scolyer, Richard A; Waddell, Nicola; Long, Georgina V.
Afiliação
  • Newell F; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Pires da Silva I; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Cancer Centre, Blacktown Hospital, Sydney, NSW 21
  • Johansson PA; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW 2065, Australia; Mater Hospital, Sydney, NSW 2060, Austr
  • Wilmott JS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
  • Addala V; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
  • Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; De
  • Rizos H; Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, NSW 2109, Australia.
  • Nones K; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Edwards JJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia.
  • Lakis V; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Kazakoff SH; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Mukhopadhyay P; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Ferguson PM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Camperdown, NSW 2050, Australia
  • Leonard C; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Koufariotis LT; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Wood S; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Blank CU; Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Thompson JF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Mater Hospital, Sydney, NSW 2060, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperd
  • Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Mater Hospital, Sydney, NSW 2060, Australia.
  • Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Mater Hospital, Sydney, NSW 2060, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperd
  • Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Mater Hospital, Sydney, NSW 2060, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
  • Pearson JV; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Mann GJ; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW 2145, Australia; John Curtin School of Medical Research, Australian National University, ACT 2601, Austral
  • Hayward NK; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
  • Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Tissue Pathology and Diagnostic Oncology, Royal P
  • Waddell N; QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia.
  • Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia; Department of Medical Oncology, Royal North Shore
Cancer Cell ; 40(1): 88-102.e7, 2022 01 10.
Article em En | MEDLINE | ID: mdl-34951955
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares / Melanoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Cell Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Austrália